Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Core Insights - Portage Biotech Inc. presented new preclinical data for PORT-7, a selective A2B receptor inhibitor, showing over 90% tumor growth inhibition when combined with an anti-PD-1 antibody in a murine mesothelioma model [1] - The company is preparing to initiate a first-in-human clinical trial for PORT-7, marking a significant step in addressing mesothelioma, an aggressive cancer with limited treatment options [1] - Portage is also advancing PORT-6, a selective A2A receptor inhibitor, with plans to co-administer it with PORT-7 in the ongoing ADPORT-601 trial to enhance immunotherapy effectiveness [2] Company Overview - Portage Biotech is a clinical-stage immuno-oncology company focused on developing novel biologics to enhance the immune system's ability to combat cancer [3]